ARYx Therapeutics Inc said it would wind down its operations due to lack of funding after the U.S. health regulator delayed providing guidance on the trial design of the company's experimental drug for gastrointestinal disorders. In its latest communication with ARYx, the U.S. Food and Drug Administration suggested that a response on the company's request for a special protocol assessment will not come in until July 2011 at the earliest. FDA was initially supposed to respond to ARYx's request on the drug, naronapride, by Nov. 5, 2010 but had informed the company that the response would be delayed until the end of March.
Source
